BridgeBio Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2834 http://bridgebio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma Inc

BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers - Oct 12th, 2021 11:30 am
BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small Cell Lung Cancer Models - Oct 7th, 2021 1:00 pm
BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021 - Oct 6th, 2021 11:30 am
Peninsula biotech looks to turn once-failed osteoporosis drug against rare disease - Oct 1st, 2021 9:57 pm
BridgeBio Pharma Announces Updated Phase 2B Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants - Oct 1st, 2021 9:00 pm
BridgeBio Pharma's Candidate For Muscle-Wasting Disorder Wins Fast Track Tag In US - Sep 15th, 2021 12:47 pm
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) - Sep 15th, 2021 11:30 am
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sep 8th, 2021 9:00 pm
Should You Be Tempted To ‘Sell’ BridgeBio Pharma (BBIO) Stock? - Aug 30th, 2021 5:36 am
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors - Aug 25th, 2021 11:00 am
10 Best Stocks to Invest In According to Chinese Billionaire Lei Zhang - Aug 23rd, 2021 2:01 pm
Baron Funds: “We Retain Conviction in BridgeBio (BBIO)” - Aug 18th, 2021 6:22 pm
BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors - Aug 18th, 2021 11:30 am
New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Aug 7th, 2021 7:07 am
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates - Aug 5th, 2021 1:05 pm
BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update - Aug 5th, 2021 11:30 am
BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations - Jul 27th, 2021 11:30 am
Hedge Funds Are Crazy About BridgeBio Pharma, Inc. (BBIO) - Jul 13th, 2021 2:42 pm
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions - Jul 8th, 2021 11:30 am
BridgeBio Pharma Stock Sees Rising Relative Strength; Still Shy Of Key Threshold - Jul 1st, 2021 6:15 pm